vs
AC Immune SA（ACIU）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Bio-Techne的季度营收约是AC Immune SA的206.0倍（$295.9M vs $1.4M）。Bio-Techne净利率更高（12.8% vs -1622.4%，领先1635.3%）。AC Immune SA同比增速更快（90.1% vs -6.4%）
AC Immune SA是一家临床阶段生物制药企业，专注于开发阿尔茨海默病、帕金森病及罕见tau蛋白病等神经退行性疾病的创新疗法与诊断方案，与全球领先药企展开合作，致力于满足神经疾病领域未被满足的临床需求。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
ACIU vs TECH — 直观对比
营收规模更大
TECH
是对方的206.0倍
$1.4M
营收增速更快
ACIU
高出96.5%
-6.4%
净利率更高
TECH
高出1635.3%
-1622.4%
损益表 — Q2 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4M | $295.9M |
| 净利润 | $-23.3M | $38.0M |
| 毛利率 | — | 64.6% |
| 营业利润率 | -1484.5% | 18.4% |
| 净利率 | -1622.4% | 12.8% |
| 营收同比 | 90.1% | -6.4% |
| 净利润同比 | 6.9% | 68.3% |
| 每股收益（稀释后） | — | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACIUTECH
| Q4 25 | — | $295.9M | ||
| Q2 25 | $1.4M | $317.0M | ||
| Q1 25 | — | $316.2M | ||
| Q4 24 | — | $297.0M | ||
| Q3 24 | — | $289.5M | ||
| Q2 24 | $755.7K | $306.1M | ||
| Q1 24 | — | $303.4M | ||
| Q4 23 | — | $272.6M |
净利润ACIUTECH
| Q4 25 | — | $38.0M | ||
| Q2 25 | $-23.3M | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | — | $33.6M | ||
| Q2 24 | $-25.0M | $40.6M | ||
| Q1 24 | — | $49.1M | ||
| Q4 23 | — | $27.5M |
毛利率ACIUTECH
| Q4 25 | — | 64.6% | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% | ||
| Q4 23 | — | 64.8% |
营业利润率ACIUTECH
| Q4 25 | — | 18.4% | ||
| Q2 25 | -1484.5% | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | -3051.1% | 15.0% | ||
| Q1 24 | — | 22.1% | ||
| Q4 23 | — | 13.9% |
净利率ACIUTECH
| Q4 25 | — | 12.8% | ||
| Q2 25 | -1622.4% | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 11.6% | ||
| Q2 24 | -3313.0% | 13.3% | ||
| Q1 24 | — | 16.2% | ||
| Q4 23 | — | 10.1% |
每股收益（稀释后）ACIUTECH
| Q4 25 | — | $0.24 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.31 | ||
| Q4 23 | — | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.3M | $172.9M |
| 总债务越低越好 | — | $260.0M |
| 股东权益账面价值 | $82.2M | $2.0B |
| 总资产 | $209.2M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ACIUTECH
| Q4 25 | — | $172.9M | ||
| Q2 25 | $28.3M | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | $56.7M | $152.9M | ||
| Q1 24 | — | $145.3M | ||
| Q4 23 | — | $135.7M |
总债务ACIUTECH
| Q4 25 | — | $260.0M | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M | ||
| Q4 23 | — | $447.0M |
股东权益ACIUTECH
| Q4 25 | — | $2.0B | ||
| Q2 25 | $82.2M | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | $135.8M | $2.1B | ||
| Q1 24 | — | $2.0B | ||
| Q4 23 | — | $2.0B |
总资产ACIUTECH
| Q4 25 | — | $2.5B | ||
| Q2 25 | $209.2M | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | $261.3M | $2.7B | ||
| Q1 24 | — | $2.7B | ||
| Q4 23 | — | $2.7B |
负债/权益比ACIUTECH
| Q4 25 | — | 0.13× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× | ||
| Q4 23 | — | 0.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACIU
暂无分部数据
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
